REFERENCES
1. Xie D, Shi J, Zhou J, Fan J, Gao Q. Clinical practice guidelines and real-life practice in hepatocellular carcinoma: a Chinese perspective. Clin Mol Hepatol. 2023;29:206-16.
2. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma. J Hepatol. 2025;82:315-74.
3. Singal AG, Llovet JM, Yarchoan M, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023;78:1922-65.
4. Tamai H, Okamura J. New next-generation microwave thermosphere ablation for small hepatocellular carcinoma. Clin Mol Hepatol. 2021;27:564-74.
5. Kim HI, An J, Han S, Shim JH. Loco-regional therapies competing with radiofrequency ablation in potential indications for hepatocellular carcinoma: a network meta-analysis. Clin Mol Hepatol. 2023;29:1013-28.
6. Iwai Y, Agala CB, Gerber DA. Integrating navigation-assisted ablation in the locoregional treatment of hepatocellular carcinoma. JAMA Netw Open. 2024;7:e240694.
7. Vitale A, Cabibbo G, Iavarone M, et al.; HCC Special Interest Group of the Italian Association for the Study of the Liver. Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept. Lancet Oncol. 2023;24:e312-22.
8. Reig M, Sanduzzi-Zamparelli M, Forner A, et al. BCLC strategy for prognosis prediction and treatment recommendations: the 2026 update. J Hepatol. 2026;84:631-54.
9. Llovet JM, Mauro E, Rimassa L, et al. Trial design and end points in hepatocellular carcinoma: an EASL-AASLD-ILCA consensus statement. Nat Rev Clin Oncol. 2026;23:619-47.
10. Aslam A, Chernyak V, Tang A, et al. CT/MRI LI-RADS 2024 update: treatment response assessment. Radiology. 2024;313:e232408.
11. Senzolo M, Shalaby S, Grasso M, et al. Role of nonneoplastic PVT in the natural history of patients with cirrhosis and first diagnosis of HCC. Hepatology. 2024;79:355-67.
12. Kodali S, Kulik L, D’Allessio A, et al.; and the ILTS ILCA Consensus 2024 Group. The 2024 ILTS-ILCA consensus recommendations for liver transplantation for HCC and intrahepatic cholangiocarcinoma. Liver Transpl. 2025;31:815-31.
13. Liao K, Yang K, Cao L, et al. Laparoscopic anatomical versus non-anatomical hepatectomy in the treatment of hepatocellular carcinoma: a randomised controlled trial. Int J Surg. 2022;102:106652.
14. Odisio BC, Albuquerque J, Lin YM, et al. Software-based versus visual assessment of the minimal ablative margin in patients with liver tumours undergoing percutaneous thermal ablation (COVER-ALL): a randomised phase 2 trial. Lancet Gastroenterol Hepatol. 2025;10:442-51.
15. Bai XM, Cui M, Yang W, et al. The 10-year survival analysis of radiofrequency ablation for solitary hepatocellular carcinoma 5 cm or smaller: primary versus recurrent HCC. Radiology. 2021;300:458-69.
16. Kawaguchi Y, Hasegawa K, Kashiwabara K, et al. Surgery versus ablation for hepatocellular carcinoma: a randomized controlled trial (SURF-RCT trial) and a nonrandomized prospective observational trial (SURF-cohort trial). J Clin Oncol. 2025;43:2628-38.
17. Fichtinger RS, Aldrighetti LA, Abu Hilal M, et al.; ORANGE II PLUS Collaborative. Laparoscopic versus open hemihepatectomy: the ORANGE II PLUS multicenter randomized controlled trial. J Clin Oncol. 2024;42:1799-809.
18. Sijberden JP, Kuemmerli C, Ratti F, et al. Laparoscopic versus open parenchymal preserving liver resections in the posterosuperior segments (ORANGE Segments): a multicentre, single-blind, randomised controlled trial. Lancet Reg Health Eur. 2025;51:101228.
19. Vitale A, Romano P, Cillo U, et al.; Writing Group for the HE.RC.O.LE.S Collaborative Group, Writing Group for the ITA.LI.CA Collaborative Group, HE.RC.O.LE.S and ITA.LI.CA Collaborative Groups. Liver resection vs nonsurgical treatments for patients with early multinodular hepatocellular carcinoma. JAMA Surg. 2024;159:881-9.
20. Wang Z, Liu M, Zhang DZ, et al. Microwave ablation versus laparoscopic resection as first-line therapy for solitary 3-5-cm HCC. Hepatology. 2022;76:66-77.
21. Kim E, Sher A, Abboud G, et al. Radiation segmentectomy for curative intent of unresectable very early to early stage hepatocellular carcinoma (RASER): a single-centre, single-arm study. Lancet Gastroenterol Hepatol. 2022;7:843-50.
22. Salem R, Johnson GE, Kim E, et al. Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY study. Hepatology. 2021;74:2342-52.
23. Xu E, Tabrizian P, Gutierrez J, et al. Downstaging of hepatocellular carcinoma before liver transplantation: results from a national multicenter prospective cohort study. Hepatology. 2025;82:612-25.
24. Mehta N, Frenette C, Tabrizian P, et al. Downstaging outcomes for hepatocellular carcinoma: results from the multicenter evaluation of reduction in tumor size before liver transplantation (MERITS-LT) consortium. Gastroenterology. 2021;161:1502-12.
25. Tan DJH, Lim WH, Yong JN, et al. UNOS down-staging criteria for liver transplantation of hepatocellular carcinoma: systematic review and meta-analysis of 25 studies. Clin Gastroenterol Hepatol. 2023;21:1475-84.
26. Lee VH, Vardhanabhuti V, Wong TC, et al. Stereotactic body radiotherapy and liver transplant for liver cancer: a nonrandomized controlled trial. JAMA Netw Open. 2024;7:e2415998.
27. Kudo M, Ren Z, Guo Y, et al.; LEAP-012 investigators. Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study. Lancet. 2025;405:203-15.
28. Sangro B, Kudo M, Erinjeri JP, et al.; EMERALD-1 Investigators. Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study. Lancet. 2025;405:216-32.
29. Peng Z, Fan W, Zhu B, et al. Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: a phase III, randomized clinical trial (LAUNCH). J Clin Oncol. 2023;41:117-27.
30. Merck & Co., Inc.; Eisai Co., Ltd. Merck and Eisai provide update on Phase 3 LEAP-012 trial in unresectable, non-metastatic hepatocellular carcinoma. 2025. Available from: https://www.merck.com/news/merck-and-eisai-provide-update-on-phase-3-leap-012-trial-in-unresectable-non-metastatic-hepatocellular-carcinoma/. [Last accessed on 22 Sep 2026].
31. Sangro B, Kudo M, Chan SL, et al. EMERALD-1: overall survival with durvalumab, bevacizumab and TACE in embolisation-eligible hepatocellular carcinoma. ESMO Gastrointestinal Cancers Congress 2026; Abstract 183O. Available from: https://oncologypro.esmo.org/video-series/emerald-1-overall-survival-with-durvalumab-bevacizumab-and-tace-in-eehcc. [Last accessed on 22 Sep 2026].
32. Lyu N, Yi JZ, Wu XT, et al. Transarterial chemoembolization plus thermal ablation in unresectable hepatocellular carcinoma: the phase 3 TORCH randomized clinical trial. JAMA Oncol. 2026;12:980-9.
33. Dhondt E, Lambert B, Hermie L, et al. 90Y radioembolization versus drug-eluting bead chemoembolization for unresectable hepatocellular carcinoma: results from the TRACE phase II randomized controlled trial. Radiology. 2022;303:699-710.
34. Xi M, Yang Z, Hu L, et al. Radiofrequency ablation versus stereotactic body radiotherapy for recurrent small hepatocellular carcinoma: a randomized, open-label, controlled trial. J Clin Oncol. 2025;43:1073-82.
35. Zhang YJ, Chen J, Zhou Z, et al. Transarterial chemoembolization with radiofrequency ablation versus surgical resection for small late-recurrence hepatocellular carcinoma. Radiology. 2025;314:e241096.
36. Singal AG, Salem R, Pinato DJ, Pillai A. Advances in locoregional and systemic treatments for hepatocellular carcinoma. Gastroenterology. 2025;169:585-99.
37. Lee IC, Wang HW, Teng W, et al.; TLCA Intermediate Stage HCC Working Group. Taiwan liver cancer association management consensus guidelines for intermediate-stage hepatocellular carcinoma. Clin Mol Hepatol. 2025;31:1213-32.
38. Zhu P, Liao W, Zhang WG, et al. A prospective study using propensity score matching to compare long-term survival outcomes after robotic-assisted, laparoscopic, or open liver resection for patients with BCLC stage 0-A hepatocellular carcinoma. Ann Surg. 2023;277:e103-11.
39. Di Benedetto F, Magistri P, Di Sandro S, et al.; Robotic HPB Study Group. Safety and efficacy of robotic vs open liver resection for hepatocellular carcinoma. JAMA Surg. 2023;158:46-54.
40. Sijberden JP, Hoogteijling TJ, Aghayan D, et al.; International consortium on Minimally Invasive Liver Surgery (I-MILS). Robotic versus laparoscopic liver resection in various settings: an international multicenter propensity score matched study of 10.075 patients. Ann Surg. 2024;280:108-17.
41. Cipriani F, Fiorentini G, Magistri P, et al. Pure laparoscopic versus robotic liver resections: multicentric propensity score-based analysis with stratification according to difficulty scores. J Hepatobiliary Pancreat Sci. 2022;29:1108-23.
42. Liu Q, Zhang W, Zhao JJ, et al.; International Robotic and Laparoscopic Liver Resection Study Group investigators. Propensity-score matched and coarsened-exact matched analysis comparing robotic and laparoscopic major hepatectomies: an international multicenter study of 4822 cases. Ann Surg. 2023;278:969-75.
43. Krenzien F, Schmelzle M, Pratschke J, et al.; International Robotic and Laparoscopic Liver Resection Study Group investigators. Propensity score-matching analysis comparing robotic versus laparoscopic limited liver resections of the posterosuperior segments: an international multicenter study. Ann Surg. 2024;279:297-305.
44. Chiow AKH, Fuks D, Choi GH, et al.; International Robotic and Laparoscopic Liver Resection Study Group collaborators. International multicentre propensity score-matched analysis comparing robotic versus laparoscopic right posterior sectionectomy. Br J Surg. 2021;108:1513-20.
45. Kamarajah SK, Bundred J, Manas D, Jiao L, Hilal MA, White SA. Robotic versus conventional laparoscopic liver resections: a systematic review and meta-analysis. Scand J Surg. 2021;110:290-300.
46. Hamad A, Eskander MF, Tsung A. What is the value of the robotic platform for major hepatectomies? JAMA Surg. 2022;157:445.
47. Chapiro J. Image-guided high-dose-rate brachytherapy for hepatocellular carcinoma could be the ultimate ablation tool. Radiology. 2024;310:e240072.
48. Lewandowski RJ, Serhal M, Padia SA, et al. The evolving application of radiation segmentectomy for the treatment of hepatic malignancy. Radiology. 2025;316:e240333.
49. Yang Z, Liu S, Hu L, et al. Stereotactic body radiotherapy is an alternative to radiofrequency ablation for single HCC ≤ 5.0 cm. JHEP Rep. 2024;6:101151.
50. Yopp A, Chen M, Cheng AL, et al. Updated data from IMbrave050: adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma. J Hepatol. 2026;84:1102-11.
51. Qin S, Chen M, Cheng AL, et al.; IMbrave050 investigators. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;402:1835-47.
52. de Baère T, Roux C, Deschamps F, Tselikas L, Guiu B. Evaluation of a new CT-guided robotic system for percutaneous needle insertion for thermal ablation of liver tumors: a prospective pilot study. Cardiovasc Intervent Radiol. 2022;45:1701-9.
53. He KS, Fernando R, Cabrera T, et al. Hepatic hilar nerve block for hepatic interventions: anatomy, technique, and initial clinical experience in thermal ablation of liver tumors. Radiology. 2021;301:223-8.
54. Li X, Zhang Y, Wang X, et al. Predicting infectious complications after percutaneous thermal ablation of liver malignancies: a 12-year single-center experience. Radiology. 2023;308:e223091.
55. Chen L, Yin J, Wang Y, et al. Time-resolved ratiometric fluorescence nanothermometer for real-time endoscopic temperature guidance during tumor ablation. Adv Mater. 2025;37:e2503726.
56. Savsani E, Shaw CM, Forsberg F, et al. Contrast-enhanced US evaluation of hepatocellular carcinoma response to chemoembolization: a prospective multicenter trial. Radiology. 2023;309:e230727.
57. Ding W, Wang Z, Liu FY, et al. A hybrid machine learning model based on semantic information can optimize treatment decision for naĂ¯ve single 3-5-cm HCC patients. Liver Cancer. 2022;11:256-67.
58. Boldanova T, Fucile G, Vosshenrich J, et al. Supervised learning based on tumor imaging and biopsy transcriptomics predicts response of hepatocellular carcinoma to transarterial chemoembolization. Cell Rep Med. 2021;2:100444.
59. Famularo S, Donadon M, Cipriani F, et al.; HE.RC.O.LE.S. Group. Machine learning predictive model to guide treatment allocation for recurrent hepatocellular carcinoma after surgery. JAMA Surg. 2023;158:192-202.
60. Lin X, Wei R, Xu Z, et al. A deep learning model for personalized intra-arterial therapy planning in unresectable hepatocellular carcinoma: a multicenter retrospective study. EClinicalMedicine. 2024;75:102808.
61. Yang J, Chen K, Zheng C, et al. Impact of sarcopenia on outcomes of patients undergoing liver resection for hepatocellular carcinoma. J Cachexia Sarcopenia Muscle. 2022;13:2383-92.
62. He YZ, He K, Huang RQ, et al. A clinical scoring system for predicting tumor recurrence after percutaneous radiofrequency ablation for 3 cm or less hepatocellular carcinoma. Sci Rep. 2021;11:8275.
63. Campani C, Imbeaud S, Couchy G, et al. Circulating tumour DNA in patients with hepatocellular carcinoma across tumour stages and treatments. Gut. 2024;73:1870-82.
64. Mendiratta-Lala M, Wiggermann P, Pech M, et al. The #HOPE4LIVER single-arm pivotal trial for histotripsy of primary and metastatic liver tumors. Radiology. 2024;312:e233051.
65. Ziemlewicz TJ, Critchfield JJ, Mendiratta-Lala M, et al. The #HOPE4LIVER single-arm pivotal trial for histotripsy of primary and metastatic liver tumors: one-year update of clinical outcomes. Ann Surg. 2025;282:908-16.
66. Abdelsalam ME, Ahrar K, Sheth RA, et al. Interventional oncology: a primer for clinicians on the role of ablation and embolization for solid tumors. CA Cancer J Clin. 2026;76:e70051.
67. Albadawi H, Zhang Z, Keum H, et al. Percutaneous delivery of oncogel for targeted liver tumor ablation and controlled release of therapeutics. Adv Mater. 2024;36:e2406080.
68. Chen Z, Meng L, Zhang J, Zhang X. Progress in the cryoablation and cryoimmunotherapy for tumor. Front Immunol. 2023;14:1094009.
69. Cheng X, He C, Huang J, et al. A tumor-homing nanoframework for synergistic microwave tumor ablation and provoking strong anticancer immunity against metastasis. ACS Nano. 2024;18:29121-39.
70. Dou WT, Qiu P, Shi Y, et al. Orthogonally engineered albumin with attenuated macrophage phagocytosis for the targeted visualization and phototherapy of liver cancer. J Am Chem Soc. 2023;145:17377-88.
71. Gong J, Hu J, Yan X, et al. Injectable hydrogels including magnetic nanosheets for multidisciplinary treatment of hepatocellular carcinoma via magnetic hyperthermia. Small. 2024;20:e2300733.
72. Hsu YC, Wu MC, Weng MT, et al. Ethanol inhibits the growth and metastasis of hepatocellular carcinoma by inducing immunogenic cell death. J Immunother Cancer. 2025;13:e010472.
73. Kan X, Zhou G, Zhang F, et al. Enhanced efficacy of direct immunochemotherapy for hepatic cancer with image-guided intratumoral radiofrequency hyperthermia. J Immunother Cancer. 2022;10:e005619.
74. Shewarega A, Santana JG, Nam D, et al. Effect of incomplete cryoablation and matrix metalloproteinase inhibition on intratumoral CD8+ T-cell infiltration in murine hepatocellular carcinoma. Radiology. 2024;310:e232365.
75. Tang X, Mao X, Ling P, et al. Glycolysis inhibition induces anti-tumor central memory CD8+T cell differentiation upon combination with microwave ablation therapy. Nat Commun. 2024;15:4665.
76. Tian Z, Hu Q, Sun Z, et al. A booster for radiofrequency ablation: advanced adjuvant therapy via in situ nanovaccine synergized with anti-programmed death ligand 1 immunotherapy for systemically constraining hepatocellular carcinoma. ACS Nano. 2023;17:19441-58.
77. Wu WS, Yan X, Chen S, et al. Minimally invasive delivery of percutaneous ablation agent via magnetic colloidal hydrogel injection for treatment of hepatocellular carcinoma. Adv Mater. 2024;36:e2309770.
78. Xu J, Zheng Q, Cheng X, et al. Chemo-photodynamic therapy with light-triggered disassembly of theranostic nanoplatform in combination with checkpoint blockade for immunotherapy of hepatocellular carcinoma. J Nanobiotechnology. 2021;19:355.
